These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9818299)

  • 1. Lack of effects of the Na+/H+ exchanger inhibitor, cariporide against myocardial stunning in exercise-induced ischemia in dogs.
    Parent de Curzon O; Ghaleh B; Giudicelli JF; Berdeaux A
    Fundam Clin Pharmacol; 1998; 12(6):646-8. PubMed ID: 9818299
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of sodium-hydrogen ion exchange in patients undergoing coronary artery bypass grafting.
    Bolli R
    J Card Surg; 2003; 18 Suppl 1():21-6. PubMed ID: 12691376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardioprotective effect of TY-12533, a novel Na(+)/H(+) exchange inhibitor, on ischemia/reperfusion injury.
    Aihara K; Hisa H; Sato T; Yoneyama F; Sasamori J; Yamaguchi F; Yoneyama S; Mizuno Y; Takahashi A; Nagai A; Kimura T; Kogi K; Satoh S
    Eur J Pharmacol; 2000 Sep; 404(1-2):221-9. PubMed ID: 10980282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational basis for use of sodium-hydrogen exchange inhibitors in myocardial ischemia.
    Avkiran M
    Am J Cardiol; 1999 May; 83(10A):10G-17G; discussion 17G-18G. PubMed ID: 10482175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of the Na+/H+ exchange inhibitor cariporide as a cardioprotective drug: from the laboratory to the GUARDIAN trial.
    Scholz W; Jessel A; Albus U
    J Thromb Thrombolysis; 1999 Jul; 8(1):61-70. PubMed ID: 10481216
    [No Abstract]   [Full Text] [Related]  

  • 6. TY-12533, a novel Na(+)/H(+) exchange inhibitor, prevents myocardial stunning in dogs.
    Aihara K; Hisa H; Sasamori J; Yoneyama F; Yamaguchi F; Satoh I; Satoh S
    Eur J Pharmacol; 2001 May; 419(1):93-7. PubMed ID: 11348635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Na(+)/H(+)-exchange inhibition and aprotinin administration: promising tools for myocardial protection during minimally invasive CABG.
    Hendrikx M; Rega F; Jamaer L; Valkenborgh T; Gutermann H; Mees U
    Eur J Cardiothorac Surg; 2001 May; 19(5):633-9. PubMed ID: 11343944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A symposium: sodium-hydrogen exchange inhibition. Introduction.
    Théroux P
    Am J Cardiol; 1999 May; 83(10A):1G-2G. PubMed ID: 10482173
    [No Abstract]   [Full Text] [Related]  

  • 9. Myocardial protection during ventricular fibrillation by inhibition of the sodium-hydrogen exchanger isoform-1.
    Gazmuri RJ; Ayoub IM; Kolarova JD; Karmazyn M
    Crit Care Med; 2002 Apr; 30(4 Suppl):S166-71. PubMed ID: 11940795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AVE4454B--a novel sodium-hydrogen exchanger isoform-1 inhibitor--compared less effective than cariporide for resuscitation from cardiac arrest.
    Radhakrishnan J; Kolarova JD; Ayoub IM; Gazmuri RJ
    Transl Res; 2011 Feb; 157(2):71-80. PubMed ID: 21256459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the Na(+)/H(+) exchanger delays the development of rapid pacing-induced atrial contractile dysfunction.
    Altemose GT; Zipes DP; Weksler J; Miller JM; Olgin JE
    Circulation; 2001 Feb; 103(5):762-8. PubMed ID: 11156891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regression of cardiomyocyte hypertrophy in SHR following chronic inhibition of the Na(+)/H(+) exchanger.
    Camilión de Hurtado MC; Portiansky EL; Pérez NG; Rebolledo OR; Cingolani HE
    Cardiovasc Res; 2002 Mar; 53(4):862-8. PubMed ID: 11922896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Na+/H+ exchange inhibitors for ischemic diseases].
    Hashimoto K
    Nihon Yakurigaku Zasshi; 2001 Dec; 118(6):363-70. PubMed ID: 11778453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) Investigators.
    Théroux P; Chaitman BR; Danchin N; Erhardt L; Meinertz T; Schroeder JS; Tognoni G; White HD; Willerson JT; Jessel A
    Circulation; 2000 Dec; 102(25):3032-8. PubMed ID: 11120691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myocardial stunning following no flow ischaemia is diminished by levosimendan or cariporide, without benefits of combined administration.
    Brendt P; Behrends M; Peters J
    Resuscitation; 2008 Jan; 76(1):95-102. PubMed ID: 17719165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic inhibition of na(+)/h(+)-exchanger in the heart.
    Baartscheer A
    Curr Vasc Pharmacol; 2006 Jan; 4(1):23-9. PubMed ID: 16472174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardioprotective therapy and sodium-hydrogen exchange inhibition: current concepts and future goals.
    Menown IB; Adgey AA
    J Am Coll Cardiol; 2001 Nov; 38(6):1651-3. PubMed ID: 11704376
    [No Abstract]   [Full Text] [Related]  

  • 18. Sodium-hydrogen exchange inhibition: novel strategy to prevent myocardial injury following ischemia and reperfusion.
    Buerke M; Rupprecht HJ; vom Dahl J; Terres W; Seyfarth M; Schultheiss HP; Richardt G; Sheehan FH; Drexler H
    Am J Cardiol; 1999 May; 83(10A):19G-22G. PubMed ID: 10482176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GUARD During Ischemia Against Necrosis (GUARDIAN) trial in acute coronary syndromes.
    Erhardt LR
    Am J Cardiol; 1999 May; 83(10A):23G-25G. PubMed ID: 10482177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of the GUARDIAN trial results: clinical implications and the significance of elevated perioperative CK-MB on 6-month survival.
    Chaitman BR
    J Card Surg; 2003; 18 Suppl 1():13-20. PubMed ID: 12691375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.